Data compiled by Redley Lamar · ChainSifter Intelligence
0Suppliers
7Customers
2Debt Items
12Related Chains
Source-Backed Evidence Depth
Praxis Precision Medicines, Inc. (PRAX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
1Distinct source URLs
4High confidence
0.754Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Praxis Precision Medicines, Inc. Suppliers
No suppliers on recordPraxis Precision Medicines, Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.
Praxis Precision Medicines, Inc. Customers
Ticker
Name
Confidence
Evidence
BCPE
BCPE
92%
The Company recorded the common stock sold to BCPE at its issuance date fair value of $ 38.95 per share, or $ 17.3 million in the aggregate
Reciprocal relationship from RAPP graph: into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufac…
Reciprocal relationship from XENE graph: Reciprocal relationship from PRAX graph: Reciprocal relationship from XENE graph: Reciprocal relationship from PRAX graph: Reciprocal relationship from XENE g…
BCPE-TENET-HOLDINGS-CAYMAN-LTD
BCPE-TENET-HOLDINGS-CAYMAN-LTD
62%
cule therapeutics as potential treatments of KCNT1-related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as p…
NASDAQ-STOCK-MARKET-LLC
NASDAQ-STOCK-MARKET-LLC
62%
o the performance obligation. The Company accounted for the excess of the fair value of the equity securities issued over the total proceeds received as consideration paid to a customer for which no …
SHANGHAI-CO-LTD
SHANGHAI-CO-LTD
62%
cule therapeutics as potential treatments of KCNT1-related epilepsies. Under the terms of the Collaboration Agreement, the Company has agreed to perform general biology-related research services as p…
USA-LLC
USA-LLC
62%
PDUFA fee paid in the first quarter of 2026. • $3.8 million increase in personnel-related costs mainly due to increased headcount; and • $3.0 million increase in expense related to our Solidus™ platf…
Praxis Precision Medicines, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PRAX-DEBT
Debt stack $1.4M
90%
Market cache reports total debt of $1.4M.
PRAX-DEBT-11873
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
Praxis Precision Medicines, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Praxis Precision Medicines, Inc..
Praxis Precision Medicines, Inc. Ownership
Holder
Name
Confidence
Evidence
PRAX-OWNER-PERCEPTIVE-ADVISORS-LLC
PERCEPTIVE ADVISORS LLC
90%
13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 300 tracked holders.
Praxis Precision Medicines, Inc. Extended Supply Chain Network
